Autism Spectrum Disorders (ASD) Treatment Market
Autism Spectrum Disorders (ASD) Treatment Market Size, Share & Trends Analysis Report by Treatment Type (Antipsychotic Drugs, Selective Serotonin Reuptake Inhibitors, Stimulants, Sleep Medications, and Others), by Application (Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder, and Others), and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) Forecast Period (2023-2030) Update Available - Forecast 2024-2030
ASD market is anticipated to grow at a considerable CAGR of 5.1% during the forecast period. The growth of the market is attributed to factors such as the increasing prevalence of autism and the development of innovative treatment options. For instance, in Jun 2019, Q BioMed Inc. founded two novel biomarkers for pediatric nonverbal autism, reportedly marking the first time a company has identified biomarkers that hold the potential to stratify an autism spectrum disorder subset of children as young as 18 months. Such discovery contribute to effective treatment for children destined with little or no ability to speak.
Segmental Outlook
The global autism spectrum disorders (ASD) treatment market is segmented based on treatment type, application, and distribution channel. Based on treatment type, the market is segmented into antipsychotic drugs, SSRIs, stimulants, sleep medications, and others. Based on the application, the market is categorized into autistic disorder, Asperger syndrome, pervasive developmental disorder, and others. Each application segment represents a distinct group within the autism spectrum and requires specific therapeutic approaches.Among these, antipsychotic drugs are anticipated to hold a prominent market share due to their effectiveness in managing behavioral symptoms associated with autism spectrum disorder.
Hospital Pharmacy is Anticipated to Register Significant Growth During the Forecast Period
Among thedistribution channel, the market is sub-segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is expected to dominate the market as it serves as a primary source of medication for ASD patients, especially for those receiving specialized care in healthcare facilities. The growth of the market is further propelled by the expansion of hospitals with specialized treatment for autism. For instance, in April 2021, Ochsner Hospital for Children Opens Multi-Disciplinary Autism Clinic. The new multi-disciplinary Autism Clinic is designed to assess children ages two through four years old for suspected Autism spectrum disorder. The multi-disciplinary team, which consists of a medical developmental specialist, a psychologist, a speech pathologist, and a social worker, works together to complete a comprehensive evaluation and if a diagnosis is made, develops a personalized treatment plan for each patient.
Regional Outlooks
The global autism spectrum disorder (ASD) treatment market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and others), Asia-Pacific (India, China, Japan, South Korea, and others), and the Rest of the World (the Middle East & Africa and Latin America). The market can be analyzed at a regional or country level as per the requirement. Among these, the Asia-Pacific region is anticipated to have a considerable share owing to the increased awareness about the autism spectrum disorder.
Global Autism Spectrum Disorders (ASD) Treatment Market Growth, by Region 2023-2030
The North American Region is anticipated to Hold a Significant Share in the Global Autism Spectrum Disorders (ASD) Treatment Market
Among all the regions, North America is anticipated to hold a significant share of the global ASD market during the forecast period. The region has a high prevalence of autism. For instance, according to a study released by the Centers for Disease Control and Prevention, the prevalence of ASD in American children rose between 2018 and 2020, continuing a long-running trend. In 2020, an estimated one in 36 (8-year-olds) had autism, up from one in 44 in 2018. The prevalence was roughly 4% in boys and 1% in girls. Additionally, the region is equipped with advanced healthcare infrastructure, supporting the diagnosis and treatment of autism.
Market Players Outlook
The major companies serving the global autism spectrum disorders (ASD) treatment market include Johnson & Johnson Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Bristol-Myers Squibb, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in May 2020, HARMAN, a wholly-owned subsidiary of Samsung Electronics Co. Ltd., entered into a multi-year, global partnership with Roche to create a digital therapeutic platform for individuals with autism spectrum disorder (ASD). This partnership will combine HARMAN and Samsung’s extensive technology and device experience with Roche’s leadership in neuroscience and developing innovative therapies. HARMAN and Roche will also seek to expand the platform for the development of other digital health products across multiple therapeutic areas.
The Report Covers
- Market value data analysis of 2022 and forecast to 2030.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global autism spectrum disorders (ASD) treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.2. Allergan Plc
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. GlaxoSmithKline plc
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Sanofi S.A.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Takeda Pharmaceutical Company Ltd.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
4. Market Segmentation
4.1. Global Autism Spectrum Disorders (ASD) Treatment Market by Treatment Type
4.1.1. Antipsychotic Drugs
4.1.2. Selective Serotonin Reuptake Inhibitors
4.1.3. Stimulants
4.1.4. Sleep Medications
4.1.5. Others
4.2. Global Autism Spectrum Disorders (ASD) Treatment Market by Application
4.2.1. Autistic Disorder
4.2.2. Asperger Syndrome
4.2.3. Pervasive Developmental Disorder
4.2.4. Others
4.3. Global Autism Spectrum Disorders (ASD) Treatment Market by Distribution Channel
4.3.1. Hospital Pharmacy
4.3.2. Retail Pharmacy
4.3.3. Online Pharmacy
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Axial Therapeutics Inc.
6.2. Bristol Myers Squibb Co.
6.3. Curemark, LLC
6.4. Eli Lilly and Company
6.5. F. Hoffman-La Roche Ltd.
6.6. Johnson & Johnson Services, Inc.
6.7. Merck & Co., Inc.
6.8. Novartis AG
6.9. Otsuka Pharmaceutical Co., Ltd.
6.10. Pfizer Inc.
6.11. Q BioMed Inc.
6.12. Roche Group
6.13. Yamo Pharmaceuticals LLC
1. GLOBAL AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
2. GLOBAL ANTIPSYCHOTIC DRUGS FOR AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
3. GLOBALAUTISM SELECTIVE SEROTONIN REUPTAKE INHIBITORS FOR AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
4. GLOBAL STIMULANTS FOR AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
5. GLOBAL SLEEP MEDICATIONS FOR AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
6. GLOBAL OTHERS FOR AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
7. GLOBAL AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
8. GLOBAL AUTISM SPECTRUM DISORDER (ASD) TREATMENT FOR AUTISTIC DISORDER MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
9. GLOBAL AUTISM SPECTRUM DISORDER (ASD) TREATMENT FOR ASPERGER SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
10. GLOBAL AUTISM SPECTRUM DISORDER (ASD) TREATMENT FOR PERVASIVE DEVELOPMENTAL DISORDER MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
11. GLOBAL AUTISM SPECTRUM DISORDER (ASD) TREATMENT FOR OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
12. GLOBAL AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
13. GLOBAL AUTISM SPECTRUM DISORDER (ASD) TREATMENT BY HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
14. GLOBAL AUTISM SPECTRUM DISORDER (ASD) TREATMENT BY RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
15. GLOBAL AUTISM SPECTRUM DISORDER (ASD) TREATMENT BY ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
16. GLOBAL AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
17. NORTH AMERICAN AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
18. NORTH AMERICAN AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
19. NORTH AMERICAN AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
20. NORTH AMERICAN AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
21. EUROPEAN AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
22. EUROPEAN AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
23. EUROPEAN AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
24. EUROPEAN AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
25. ASIA-PACIFIC AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
26. ASIA-PACIFIC AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
27. ASIA-PACIFIC AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
28. ASIA-PACIFIC AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
29. REST OF THE WORLD AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
30. REST OF THE WORLD AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
31. REST OF THE WORLD AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
32. REST OF THE WORLD AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
1. GLOBAL AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SHARE BY TREATMENT TYPE, 2022 VS 2030 (%)
2. GLOBAL ANTIPSYCHOTIC DRUGS FOR AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
3. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS FOR AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
4. GLOBAL STIMULANTS FOR AUTISM SPECTRUM DISORDER (ASD) TREATMENT BY MARKET SHARE REGION, 2022 VS 2030 (%)
5. GLOBAL SLEEP MEDICATIONS FOR AUTISM SPECTRUM DISORDER (ASD) TREATMENT BY MARKET SHARE REGION, 2022 VS 2030 (%)
6. GLOBAL OTHERS FOR AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SHARE REGION, 2022 VS 2030 (%)
7. GLOBAL AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SHARE BY APPLICATION, 2022 VS 2030 (%)
8. GLOBALAUTISM SPECTRUM DISORDER (ASD) TREATMENT FOR AUTISTIC DISORDER MARKET SHARE BY REGION, 2022 VS 2030 (%)
9. GLOBAL AUTISM SPECTRUM DISORDER (ASD) TREATMENT FOR ASPERGER SYNDROME MARKET SHARE BY REGION, 2022 VS 2030 (%)
10. GLOBALAUTISM SPECTRUM DISORDER (ASD) TREATMENT FOR PERVASIVE DEVELOPMENTAL DISORDER MARKET SHARE BY REGION, 2022 VS 2030 (%)
11. GLOBALAUTISM SPECTRUM DISORDER (ASD) TREATMENT FOR OTHERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
12. GLOBAL AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SHARE BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
13. GLOBAL AUTISM SPECTRUM DISORDER (ASD) TREATMENT BY HOSPITAL PHARMACY MARKET SHARE BY REGION, 2022 VS 2030 (%)
14. GLOBAL AUTISM SPECTRUM DISORDER (ASD) TREATMENT BY RETAIL PHARMACY MARKET SHARE BY REGION, 2022 VS 2030 (%)
15. GLOBAL AUTISM SPECTRUM DISORDER (ASD) TREATMENT BY ONLINE PHARMACY MARKET SHARE BY REGION, 2022 VS 2030 (%)
16. GLOBAL AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
17. US AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
18. CANADA AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
19. UK AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
20. FRANCE AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
21. GERMANY AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
22. ITALY AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
23. SPAIN AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
24. REST OF EUROPE AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
25. INDIA AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
26. CHINA AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
27. JAPAN AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
28. SOUTH KOREA AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
29. REST OF ASIA-PACIFIC AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
30. REST OF THE WORLD AUTISM SPECTRUM DISORDER (ASD) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
